Work

Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.3028

Authors: J. Baselga, F. Rojo, H. Dumez, A. Mita, C. H. Takimoto, J. Tabernero, C. Dilea, K. Parker, M. Dugan, A. T. van Oosterom

Institutions: Vall d'Hebron Hospital Universitari, Novartis (Spain), KU Leuven

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2254255083

Cites:

Cited by: 26

Related to: 10